A Single-arm, Open-label, Phase II Study to Evaluate Efficacy, Safety and Pharmacokinetics of HLX10 + Chemotherapy in Patients With ES-SCLC
Clinical trial NCT06812260 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06812260
- Sponsor
- Shanghai Henlius Biotech
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-06-24
- Primary completion
- 2026-10-22
- Enrollment
- 26
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.